Etalanetug is a monoclonal antibody commercialized by Eisai, with a leading Phase III program in Alzheimer’s Disease;Dementia. According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Etalanetug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Etalanetug is expected to reach an annual total of $40 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Etalanetug Overview
etalanetug (E-2814) is under development for the treatment of Alzheimer's disease and dementia. The drug candidate acts by targeting TAU protein and administered through intravenous route.
Eisai Overview
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include LEQEMBI for the treatment of early-stage Alzheimer’s disease; Lenvima for treatment of endometrial carcinoma; Dayvigo which is being developed for the treatment of insomnia; Halaven, an anti-cancer agent; and Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US, and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY741,751 million for the fiscal year ended March 2024 (FY2024), a decrease of 0.4% over FY2023. In FY2024, the company’s operating margin was 7.2%, compared to an operating margin of 5.4% in FY2023. In FY2024, the company recorded a net margin of 5.7%, compared to a net margin of 7.4% in FY2023.
The company reported revenues of JPY189,029 million for the first quarter ended June 2024, a decrease of 0.8% over the previous quarter.
For a complete picture of Etalanetug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
